SMS Pharmaceuticals Limited (IN:SMSPHARMA)
:SMSPHARMA
Top Page
SMS Pharmaceuticals Limited
(SMSPHARMA)
Select Model
Select Model
Rating:70Outperform
Price Target:
₹402.00
▲(23.54% Upside)
Action:UpgradedDate:03/11/26
The score is driven primarily by improving price trend and bullish technical momentum, while financial performance is mixed due to volatile net income and inconsistent free cash flow. Valuation is moderate-to-stretched on earnings (P/E ~30) but supported by a high dividend yield.
Positive Factors
Steady Revenue Growth
Consistent revenue growth from 2020–2025 indicates durable demand for the company's API portfolio and expanding market penetration. Over 2–6 months this supports stable capacity utilization, stronger supplier/customer bargaining, and predictable scale benefits that underpin long-term cash generation and strategic investment.
Negative Factors
Volatile Net Income
A pronounced net income decline in 2023 that produced a negative net margin undermines earnings quality and predictability. For management and investors this raises concerns about cost control, product mix risks, or one-off losses, complicating long-term planning for capex, dividends, and strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Growth
Consistent revenue growth from 2020–2025 indicates durable demand for the company's API portfolio and expanding market penetration. Over 2–6 months this supports stable capacity utilization, stronger supplier/customer bargaining, and predictable scale benefits that underpin long-term cash generation and strategic investment.
Read all positive factors
SMS Pharmaceuticals Limited (SMSPHARMA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹36.41B
Dividend Yield0.13%
Average Volume (3M)105.50K
Price to Earnings (P/E)30.0
Beta (1Y)1.54
Revenue Growth11.91%
EPS Growth36.92%
CountryIN
Employees1,197
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.51
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.91
Price to Sales (P/S)2.38
P/FCF Ratio-31.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SMS Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, anti...
How the Company Makes Money
SMS Pharmaceuticals primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) and related intermediates to pharmaceutical companies that use these materials to produce finished dosage medicines (e.g., tablets/caps...
SMS Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.60B | 7.83B | 7.09B | 5.22B | 5.15B | 5.61B |
| Gross Profit | 2.49B | 1.45B | 2.11B | 1.29B | 1.81B | 1.81B |
| EBITDA | 1.67B | 1.45B | 1.18B | 593.89M | 1.20B | 1.25B |
| Net Income | 843.60M | 691.36M | 498.26M | -70.59M | 622.20M | 625.27M |
Balance Sheet | ||||||
| Total Assets | 12.76B | 11.53B | 10.34B | 8.80B | 8.60B | 8.12B |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 415.86M | 361.16M | 73.78M | 465.83M | 404.23M |
| Total Debt | 3.24B | 3.11B | 2.81B | 2.54B | 2.63B | 2.55B |
| Total Liabilities | 5.47B | 5.13B | 4.98B | 4.19B | 3.89B | 4.02B |
| Stockholders Equity | 7.29B | 6.40B | 5.36B | 4.61B | 4.70B | 4.11B |
Cash Flow | ||||||
| Free Cash Flow | 126.58M | -588.57M | -20.35M | -74.71M | 129.86M | -612.96M |
| Operating Cash Flow | 423.25M | 645.23M | 501.25M | 224.50M | 402.34M | 904.53M |
| Investing Cash Flow | -305.04M | -1.24B | -520.72M | -296.86M | -271.53M | -1.52B |
| Financing Cash Flow | 462.69M | 644.32M | 306.79M | -319.69M | -69.21M | 920.18M |
SMS Pharmaceuticals Limited Technical Analysis
Positive
325.40
Price Trends
355.79
Positive
333.68
Positive
293.67
Positive
Market Momentum
7.15
Positive
53.61
Neutral
43.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SMSPHARMA, the sentiment is Positive. The current price of 325.4 is below the 20-day moving average (MA) of 385.10, below the 50-day MA of 355.79, and above the 200-day MA of 293.67, indicating a bullish trend. The MACD of 7.15 indicates Positive momentum. The RSI at 53.61 is Neutral, neither overbought nor oversold. The STOCH value of 43.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SMSPHARMA.
SMS Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹36.41B | 29.96 | ― | 0.13% | 11.91% | 36.92% | |
57 Neutral | ₹20.81B | 20.54 | ― | 0.49% | -0.29% | -29.04% | |
54 Neutral | ₹23.98B | 205.09 | ― | 0.92% | ― | ― | |
54 Neutral | ₹22.89B | -36.05 | ― | ― | -4.18% | ― | |
53 Neutral | ₹9.82B | 20.91 | ― | 0.24% | 13.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹17.32B | -18.14 | ― | 0.08% | -2.81% | -444.69% |
* Healthcare Sector Average
IN:SMSPHARMA
SMS Pharmaceuticals Limited
388.75
191.32
96.91%
IN:BAJAJHCARE
Bajaj Healthcare Ltd
311.05
-257.56
-45.30%
IN:INDOCO
Indoco Remedies Limited
187.60
-46.23
-19.77%
IN:MEDIASSIST
Medi Assist Healthcare Services Limited
321.40
-125.85
-28.14%
IN:MOREPENLAB
Morepen Laboratories Limited
37.98
-9.62
-20.21%
IN:SOLARA
Solara Active Pharma Sciences Ltd.
475.15
-19.50
-3.94%
SMS Pharmaceuticals Limited Corporate Events
SMS Pharmaceuticals opens SEBI-backed window for legacy physical share transfers
Mar 20, 2026
SMS Pharmaceuticals Limited has notified stock exchanges that, pursuant to a recent SEBI circular, a special window has been re-opened for re-lodgement of physical share transfer requests. The facility applies only to transfer deeds originally lod...
SMS Pharmaceuticals Sets Up Wholly Owned Subsidiary SMS coLab for Greenfield Pharma Expansion
Dec 24, 2025
SMS Pharmaceuticals Limited has incorporated a new wholly owned subsidiary, SMS coLab Private Limited, following approval from the Ministry of Corporate Affairs on 23 December 2025, with an authorised capital of Rs. 15 lakh and paid-up capital of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.